vs
Side-by-side financial comparison of Royalty Pharma plc (RPRX) and WYNDHAM HOTELS & RESORTS, INC. (WH). Click either name above to swap in a different company.
Royalty Pharma plc is the larger business by last-quarter revenue ($622.0M vs $334.0M, roughly 1.9× WYNDHAM HOTELS & RESORTS, INC.). Royalty Pharma plc runs the higher net margin — 34.4% vs -18.0%, a 52.4% gap on every dollar of revenue. On growth, Royalty Pharma plc posted the faster year-over-year revenue change (4.8% vs -76.3%). Over the past eight quarters, Royalty Pharma plc's revenue compounded faster (4.6% CAGR vs -4.6%).
Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.
Wyndham Hotels & Resorts, Inc., is an American hospitality company based in Parsippany, New Jersey, United States. It describes itself as the largest hotel franchisor in the world, with 9,100 locations.
RPRX vs WH — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $622.0M | $334.0M |
| Net Profit | $214.2M | $-60.0M |
| Gross Margin | — | — |
| Operating Margin | 62.4% | — |
| Net Margin | 34.4% | -18.0% |
| Revenue YoY | 4.8% | -76.3% |
| Net Profit YoY | 2.9% | -170.6% |
| EPS (diluted) | $0.49 | $-0.80 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $334.0M | ||
| Q4 25 | $622.0M | $334.0M | ||
| Q3 25 | $609.3M | $382.0M | ||
| Q2 25 | $578.7M | $397.0M | ||
| Q1 25 | $568.2M | $316.0M | ||
| Q4 24 | $593.6M | $336.0M | ||
| Q3 24 | $564.7M | $396.0M | ||
| Q2 24 | $537.3M | $367.0M |
| Q1 26 | — | $-60.0M | ||
| Q4 25 | $214.2M | $-60.0M | ||
| Q3 25 | $288.2M | $105.0M | ||
| Q2 25 | $30.2M | $87.0M | ||
| Q1 25 | $238.3M | $61.0M | ||
| Q4 24 | $208.2M | $85.0M | ||
| Q3 24 | $544.0M | $102.0M | ||
| Q2 24 | $102.0M | $86.0M |
| Q1 26 | — | — | ||
| Q4 25 | 62.4% | -11.4% | ||
| Q3 25 | 70.1% | 46.6% | ||
| Q2 25 | 36.3% | 37.8% | ||
| Q1 25 | 94.0% | 35.4% | ||
| Q4 24 | 60.9% | 38.4% | ||
| Q3 24 | — | 43.2% | ||
| Q2 24 | 50.2% | 39.5% |
| Q1 26 | — | -18.0% | ||
| Q4 25 | 34.4% | -18.0% | ||
| Q3 25 | 47.3% | 27.5% | ||
| Q2 25 | 5.2% | 21.9% | ||
| Q1 25 | 41.9% | 19.3% | ||
| Q4 24 | 35.1% | 25.3% | ||
| Q3 24 | 96.3% | 25.8% | ||
| Q2 24 | 19.0% | 23.4% |
| Q1 26 | — | $-0.80 | ||
| Q4 25 | $0.49 | $-0.77 | ||
| Q3 25 | $0.67 | $1.36 | ||
| Q2 25 | $0.07 | $1.13 | ||
| Q1 25 | $0.55 | $0.78 | ||
| Q4 24 | $0.46 | $1.06 | ||
| Q3 24 | $1.21 | $1.29 | ||
| Q2 24 | $0.23 | $1.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $618.7M | $64.0M |
| Total DebtLower is stronger | $9.0B | — |
| Stockholders' EquityBook value | $9.7B | $468.0M |
| Total Assets | $19.6B | $4.2B |
| Debt / EquityLower = less leverage | 0.92× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $64.0M | ||
| Q4 25 | $618.7M | $64.0M | ||
| Q3 25 | $938.9M | $70.0M | ||
| Q2 25 | $631.9M | $50.0M | ||
| Q1 25 | $1.1B | $48.0M | ||
| Q4 24 | $929.0M | $103.0M | ||
| Q3 24 | $950.1M | $72.0M | ||
| Q2 24 | $1.8B | $70.0M |
| Q1 26 | — | — | ||
| Q4 25 | $9.0B | $2.5B | ||
| Q3 25 | $8.9B | $2.6B | ||
| Q2 25 | $8.0B | $2.5B | ||
| Q1 25 | $7.6B | $2.5B | ||
| Q4 24 | $7.6B | $2.4B | ||
| Q3 24 | $7.6B | $2.4B | ||
| Q2 24 | $7.6B | $2.4B |
| Q1 26 | — | $468.0M | ||
| Q4 25 | $9.7B | $468.0M | ||
| Q3 25 | $9.6B | $583.0M | ||
| Q2 25 | $9.5B | $570.0M | ||
| Q1 25 | $9.8B | $579.0M | ||
| Q4 24 | $10.3B | $650.0M | ||
| Q3 24 | $10.3B | $583.0M | ||
| Q2 24 | $9.8B | $623.0M |
| Q1 26 | — | $4.2B | ||
| Q4 25 | $19.6B | $4.2B | ||
| Q3 25 | $19.3B | $4.3B | ||
| Q2 25 | $18.3B | $4.3B | ||
| Q1 25 | $17.6B | $4.2B | ||
| Q4 24 | $18.2B | $4.2B | ||
| Q3 24 | $18.0B | $4.2B | ||
| Q2 24 | $17.7B | $4.2B |
| Q1 26 | — | — | ||
| Q4 25 | 0.92× | 5.37× | ||
| Q3 25 | 0.93× | 4.43× | ||
| Q2 25 | 0.84× | 4.44× | ||
| Q1 25 | 0.78× | 4.29× | ||
| Q4 24 | 0.74× | 3.72× | ||
| Q3 24 | 0.74× | 4.19× | ||
| Q2 24 | 0.78× | 3.83× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $827.1M | $367.0M |
| Free Cash FlowOCF − Capex | — | $168.0M |
| FCF MarginFCF / Revenue | — | 50.3% |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | 3.86× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $437.0M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $367.0M | ||
| Q4 25 | $827.1M | $152.0M | ||
| Q3 25 | $702.6M | $86.0M | ||
| Q2 25 | $364.0M | $70.0M | ||
| Q1 25 | $596.1M | $59.0M | ||
| Q4 24 | $742.5M | $134.0M | ||
| Q3 24 | $703.6M | $79.0M | ||
| Q2 24 | $658.2M | $1.0M |
| Q1 26 | — | $168.0M | ||
| Q4 25 | — | $136.0M | ||
| Q3 25 | — | $75.0M | ||
| Q2 25 | — | $58.0M | ||
| Q1 25 | — | $52.0M | ||
| Q4 24 | — | $109.0M | ||
| Q3 24 | — | $71.0M | ||
| Q2 24 | — | $-6.0M |
| Q1 26 | — | 50.3% | ||
| Q4 25 | — | 40.7% | ||
| Q3 25 | — | 19.6% | ||
| Q2 25 | — | 14.6% | ||
| Q1 25 | — | 16.5% | ||
| Q4 24 | — | 32.4% | ||
| Q3 24 | — | 17.9% | ||
| Q2 24 | — | -1.6% |
| Q1 26 | — | — | ||
| Q4 25 | — | 4.8% | ||
| Q3 25 | — | 2.9% | ||
| Q2 25 | — | 3.0% | ||
| Q1 25 | — | 2.2% | ||
| Q4 24 | — | 7.4% | ||
| Q3 24 | — | 2.0% | ||
| Q2 24 | — | 1.9% |
| Q1 26 | — | — | ||
| Q4 25 | 3.86× | — | ||
| Q3 25 | 2.44× | 0.82× | ||
| Q2 25 | 12.06× | 0.80× | ||
| Q1 25 | 2.50× | 0.97× | ||
| Q4 24 | 3.57× | 1.58× | ||
| Q3 24 | 1.29× | 0.77× | ||
| Q2 24 | 6.45× | 0.01× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
WH
| Fee-related and other revenues | $334.0M | 100% |
| Management and other fees | $2.0M | 1% |
